Dr. Benjamin Lin, MD

Dr. Lin practices at Ophthalmology Surgery Center of Dallas in Dallas, Texas.

Dr. Lin's NPI, 1801355888, was assigned on March 18, 2019. Dr. Lin graduated from University of California, Geffen School of Medicine in 2019. Dr. Lin holds Florida license ME161857.

Dr. Lin's primary practice is Ophthalmology Surgery Center of Dallas, at 10740 North Central Expressway, Dallas, TX 75231. The practice phone is (214) 750-9288.

Dr. Lin's primary practice is Ophthalmology Surgery Center of Dallas in Dallas, Texas. Dr. Lin is also affiliated with Texas Health Dallas. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Lin to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 5 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Lin is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Lin's licenses on file in 3 states: Florida, California and Texas.

CMS data shows 229 Medicare services from Dr. Lin across 6 procedure codes in 2024, for 231 Medicare patients. Medicare paid $16,394 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 231 Medicare patients who saw Dr. Lin in 2024. The largest group is 65 to 74, with 96 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 32% are also on Medicaid. Their average risk score is 1.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 69, with 52% women.

In 2024, Dr. Lin wrote 1,097 Medicare Part D claims for 292 patients. 72% of them were for generic drugs. CMS names the drug for 1,017 of them, across 18 drugs with 11 or more claims each, at $41,075 in total drug cost. In 2023, CMS named 576 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Lin for performance year 2024, reported as part of a group. Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 19 papers to Dr. Lin, published from 2013 to 2025. 2023 was the busiest year, with 6. The most frequent topics are Fluorescein Angiography, Fundus Oculi and Ophthalmology. Dr. Lin has published most often in J Acad Ophthalmol (2017). Dr. Lin's most frequent co-authors are Jayanth Srinivasan-Kasi Sridhar, MD, Hasenin Raid Hashim Al-Khersan, MD and Harry W. Flynn, MD.

CMS Open Payments shows 31 general payments to Dr. Lin from 11 drug and device companies from 2023 to 2025. Food and beverage make up the largest share, 100% of the total. Alcon Laboratories Inc paid the most, $1,041.

Dr. Lin graduated from University of California, Geffen School of Medicine in 2019.

Dr. Lin is in network with 8 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.